FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093574272> ?p ?o ?g. }

• W3093574272 endingPage "e93" @default.
• W3093574272 startingPage "e93" @default.
• W3093574272 abstract "Stereotactic body radiotherapy (SBRT) is a standard option for medically inoperable stage I non-small cell lung cancer (NSCLC). However, interstitial pneumonia (IP) is considered to be a relative contraindication for SBRT. The rates of Grade ≥3 pneumonitis after SBRT in patients with IP have been reported to range from 10% to 38%. Proton beam therapy (PBT) might have an advantage in treating patients with IP. The purpose of this study is to clarify the safety and the effectiveness of PBT for Stage I NSCLC in patients with IP. Six hundred sixty-nine patients with histologically or clinically diagnosed Stage I NSCLC according to the 7th edition of UICC received passive-scattering PBT from April 2004 and December 2013 at 8 institutions in Japan. Of them, 51 patients with comorbidity of IP, which was diagnosed by CT findings, were identified and retrospectively analyzed survivals, local control, and adverse events. Forty-six (90.2%) of 51 patients were male, with a median age of 75 years (range, 60–89 years). Ten (19.6%) patients required corticosteroids or immunosuppressants, and 4 (7.8%) patients received long-term oxygen therapy. NSCLC was histologically confirmed in 32 (62.7%) patients. Clinical T stages included T1a (n = 19; 37.2%), T1b (n = 14; 27.4%), and T2a (n = 18; 35.3%). The total irradiation doses of PBT ranged from 89.3 to 131.3 Gy (RBE) BED10 (median, 109.6 Gy (RBE)). The median follow-up period was 25.1 months (range, 3.1-65.9 months) for all patients. The 2-year overall survival, disease specific survival, progression-free survival, and local progression-free rates for all patients were 71.6% (95% confidence interval [CI]: 56.9–82.8%), 83.9% (95% CI: 69.7–92.1%), 52.2% (95% CI: 38.2–65.9%), and 82.0% (95% CI: 66.5–91.2%), respectively. The incidence of Grade 2, 3, 4, and 5 pneumonitis including exacerbation of IP was 13.7%, 0%, 0%, and 3.9%, respectively. The incidence of Grade 3 dermatitis was 2.0%. No Grade 4 or severe adverse events, other than pneumonitis, were observed. PBT for Stage I NSCLC in patients with IP seems to be tolerable and effective." @default.
• W3093574272 created "2020-10-29" @default.
• W3093574272 creator A5000117746 @default.
• W3093574272 creator A5002423375 @default.
• W3093574272 creator A5005492528 @default.
• W3093574272 creator A5018944066 @default.
• W3093574272 creator A5020793018 @default.
• W3093574272 creator A5032604058 @default.
• W3093574272 creator A5058935732 @default.
• W3093574272 creator A5070732334 @default.
• W3093574272 creator A5074150160 @default.
• W3093574272 creator A5078785291 @default.
• W3093574272 creator A5079971690 @default.
• W3093574272 creator A5081587339 @default.
• W3093574272 creator A5082925421 @default.
• W3093574272 creator A5087824756 @default.
• W3093574272 creator A5089388982 @default.
• W3093574272 creator A5091639568 @default.
• W3093574272 date "2020-11-01" @default.
• W3093574272 modified "2023-09-26" @default.
• W3093574272 title "Clinical Outcomes of Proton Beam Therapy for Stage I Lung Cancer in Patients with Interstitial Pneumonia: A Multi-Institutional Retrospective Study in Japan" @default.
• W3093574272 doi "https://doi.org/10.1016/j.ijrobp.2020.07.1196" @default.
• W3093574272 hasPublicationYear "2020" @default.
• W3093574272 type Work @default.
• W3093574272 sameAs 3093574272 @default.
• W3093574272 citedByCount "0" @default.
• W3093574272 crossrefType "journal-article" @default.
• W3093574272 hasAuthorship W3093574272A5000117746 @default.
• W3093574272 hasAuthorship W3093574272A5002423375 @default.
• W3093574272 hasAuthorship W3093574272A5005492528 @default.
• W3093574272 hasAuthorship W3093574272A5018944066 @default.
• W3093574272 hasAuthorship W3093574272A5020793018 @default.
• W3093574272 hasAuthorship W3093574272A5032604058 @default.
• W3093574272 hasAuthorship W3093574272A5058935732 @default.
• W3093574272 hasAuthorship W3093574272A5070732334 @default.
• W3093574272 hasAuthorship W3093574272A5074150160 @default.
• W3093574272 hasAuthorship W3093574272A5078785291 @default.
• W3093574272 hasAuthorship W3093574272A5079971690 @default.
• W3093574272 hasAuthorship W3093574272A5081587339 @default.
• W3093574272 hasAuthorship W3093574272A5082925421 @default.
• W3093574272 hasAuthorship W3093574272A5087824756 @default.
• W3093574272 hasAuthorship W3093574272A5089388982 @default.
• W3093574272 hasAuthorship W3093574272A5091639568 @default.
• W3093574272 hasBestOaLocation W30935742721 @default.
• W3093574272 hasConcept C126322002 @default.
• W3093574272 hasConcept C126838900 @default.
• W3093574272 hasConcept C142724271 @default.
• W3093574272 hasConcept C146357865 @default.
• W3093574272 hasConcept C151730666 @default.
• W3093574272 hasConcept C167135981 @default.
• W3093574272 hasConcept C197934379 @default.
• W3093574272 hasConcept C204787440 @default.
• W3093574272 hasConcept C2776256026 @default.
• W3093574272 hasConcept C2776494729 @default.
• W3093574272 hasConcept C2777714996 @default.
• W3093574272 hasConcept C2777793932 @default.
• W3093574272 hasConcept C2779524853 @default.
• W3093574272 hasConcept C509974204 @default.
• W3093574272 hasConcept C71924100 @default.
• W3093574272 hasConcept C86803240 @default.
• W3093574272 hasConceptScore W3093574272C126322002 @default.
• W3093574272 hasConceptScore W3093574272C126838900 @default.
• W3093574272 hasConceptScore W3093574272C142724271 @default.
• W3093574272 hasConceptScore W3093574272C146357865 @default.
• W3093574272 hasConceptScore W3093574272C151730666 @default.
• W3093574272 hasConceptScore W3093574272C167135981 @default.
• W3093574272 hasConceptScore W3093574272C197934379 @default.
• W3093574272 hasConceptScore W3093574272C204787440 @default.
• W3093574272 hasConceptScore W3093574272C2776256026 @default.
• W3093574272 hasConceptScore W3093574272C2776494729 @default.
• W3093574272 hasConceptScore W3093574272C2777714996 @default.
• W3093574272 hasConceptScore W3093574272C2777793932 @default.
• W3093574272 hasConceptScore W3093574272C2779524853 @default.
• W3093574272 hasConceptScore W3093574272C509974204 @default.
• W3093574272 hasConceptScore W3093574272C71924100 @default.
• W3093574272 hasConceptScore W3093574272C86803240 @default.
• W3093574272 hasIssue "3" @default.
• W3093574272 hasLocation W30935742721 @default.
• W3093574272 hasOpenAccess W3093574272 @default.
• W3093574272 hasPrimaryLocation W30935742721 @default.
• W3093574272 hasRelatedWork W2133367262 @default.
• W3093574272 hasRelatedWork W2233648844 @default.
• W3093574272 hasRelatedWork W2277416945 @default.
• W3093574272 hasRelatedWork W2365632055 @default.
• W3093574272 hasRelatedWork W2366314651 @default.
• W3093574272 hasRelatedWork W2373558336 @default.
• W3093574272 hasRelatedWork W2394006323 @default.
• W3093574272 hasRelatedWork W3031152052 @default.
• W3093574272 hasRelatedWork W3091031604 @default.
• W3093574272 hasRelatedWork W4307349053 @default.
• W3093574272 hasVolume "108" @default.
• W3093574272 isParatext "false" @default.
• W3093574272 isRetracted "false" @default.
• W3093574272 magId "3093574272" @default.
• W3093574272 workType "article" @default.